Advertisements

Femistad

Quick links to important sections

Femistad

Advertisements

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Femistad

Property Description
Active Ingredients Desogestrel, Ethinyl Estradiol
Form Oral tablet (Film-coated)
Pharmacological Class Combined Hormonal Contraceptive (CHC)
Common Use Prevention of pregnancy (Contraception)
Origin Synthetic hormonal preparation

What Type of Medicine is Femistad? (Classification and Origin)

Femistad is a prescription-only medicine classified as a Combined Hormonal Contraceptive (CHC). This synthetic preparation belongs to the pharmacological class of Sex hormones and modulators of the genital system (WHO ATC Code G03). As an oral tablet, its primary function is to serve as hormonal birth control and reliably prevent pregnancy. The formulation is clinically recognized for its role in establishing effective systemic hormonal regulation. This highlights the drug's foundational utility as a widely used method for family planning, specifically targeting women of childbearing age requiring an oral contraceptive solution.

Composition: Desogestrel and Ethinyl Estradiol

The essential composition of Femistad is a combination of two active synthetic ingredients, the progestin Desogestrel and the estrogen Ethinyl Estradiol. Desogestrel is classified as a third-generation synthetic progestin, which, when combined with the potent synthetic estrogen, Ethinyl Estradiol, forms the basis of its contraceptive action. This pairing is a standard type of combined hormonal contraceptive designed for systemic effect. Typically, Femistad is a monophasic oral contraceptive, meaning the amount of both hormones remains consistent across all active tablets in the cycle, providing consistent daily hormonal exposure.

How Does Femistad Function as a Contraceptive? (General Mechanism Principle)

The general utility of Femistad is achieved by regulating the female reproductive system to establish multiple barriers against conception. The combined synthetic hormones work primarily by systemically suppressing the natural cycle, leading to the inhibition of ovulation—preventing the ovary from releasing an egg. The progestin component, Desogestrel, also contributes by thickening the cervical mucus, which physically impedes sperm from traveling toward the uterus. These actions collectively reinforce the product's effectiveness as a reliable form of hormonal contraception for women.

Regulatory References

  1. National Institutes of Health (NIH)
Advertisements

What side effects are possible with Femistad?

Safety Profile and Serious Adverse Reactions

Femistad, which contains a combination of levonorgestrel and ethinyl estradiol, has a well-documented safety profile primarily characterized by a risk of serious cardiovascular and thrombotic events.

Serious and Clinically Significant Risks

The most significant and serious risks are venous and arterial thromboembolic disorders, including deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, and myocardial infarction. The risk of these events is substantially increased in women over the age of 35 who smoke.

Other serious conditions linked to combination oral contraceptive use include the potential for liver tumors (hepatic adenomas), breast cancer, and the development or worsening of hypertension (high blood pressure) and gallbladder disease.

Common Side Effects

Common adverse reactions frequently reported in clinical studies fall primarily under the nervous system, gastrointestinal system, and reproductive system. These may include:

  • Headache
  • Nausea and abdominal pain
  • Vaginal moniliasis, pain, or vaginitis
  • Metrorrhagia (irregular uterine bleeding) or spotting
  • Acne

Safety Restrictions and Monitoring

Femistad is contraindicated for use in individuals with a history of or current conditions such as uncontrolled high blood pressure, known or suspected estrogen- or progestin-sensitive cancers, and severe liver disease.

Regulatory documents emphasize necessary safety monitoring, including evaluation of cardiovascular risk factors prior to initiation, routine blood pressure checks, and discontinuation if symptoms of a thrombotic event, jaundice, or severe, new-onset headaches occur. The medicine is not indicated for use in elderly women.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for Femistad (Desogestrel and Ethinyl Estradiol) consistently indicates that an acute over-exposure is generally not associated with serious adverse effects or mortality. The officially documented clinical manifestations primarily affect the gastrointestinal and reproductive systems.

Documented Overdose Presentations

The documented signs and symptoms of acute overdose are typically limited to:

  • Nausea
  • Vomiting
  • Vaginal bleeding (often referred to as withdrawal bleeding)

A specific population consideration noted in regulatory documents is that vaginal bleeding may also occur in pre-pubertal girls.

Emergency Response and Management

The severity classification is low, reflecting the non-life-threatening nature of the acute event; however, immediate action is required upon suspicion of overdose. Regulatory guidance explicitly states to seek medical attention immediately and to contact a poison control center or emergency room at once.

The mandated procedure is symptomatic and supportive treatment, as no specific antidote is known. Monitoring of vital signs may be required in the event of an emergency visit.

This official overdose profile establishes that while acute over-ingestion carries a low risk of severe systemic harm, emergency medical attention is mandatory. Management must focus on alleviating the specific manifestations (nausea, vomiting, bleeding) while maintaining stability, consistent with the lack of a targeted reversal agent described in prescribing information.

Advertisements

Therapeutic Uses of Femistad

What Femistad Treats: Main Uses and Benefits

The medication is commonly used to help with prevention of pregnancy through reliable hormonal birth control, establishing a systemic and long-term method for family planning.

Combined hormonal contraceptives are also commonly used across conditions characterized by periods of heightened symptoms of the menstrual cycle.

Femistad assists with managing symptoms related to cyclical discomfort and reproductive irregularity, including dysmenorrhea (painful periods) and is relevant for easing heavy or irregular menstrual flow. Furthermore, it is applied in addressing symptoms related to hormone-sensitive domains, such as the recurring distress of Premenstrual Syndrome (PMS) and dermatological manifestations like acne vulgaris and hirsutism (excessive hair growth).

This use is generally applied when supportive symptom management is appropriate, as it helps improve day-to-day comfort during symptomatic periods, assisting with maintaining functional stability.


Quick Fact: Supportive Management for Cyclical Discomfort

The medication is commonly used to help with the symptomatic relief of painful menstrual cramps and supports a sense of stability in flow patterns.

Regulatory References

  1. MedlinePlus Medical Encyclopedia overview
Advertisements

Eligibility and Restrictions for Use

Femistad, which contains tranexamic acid, is primarily used to manage heavy menstrual bleeding (menorrhagia) in women. It is generally suitable for most adult women experiencing this condition and may be prescribed for adolescents after the start of menstruation. The medicine works by promoting blood clotting, which helps reduce excessive blood flow.


Contraindications

There are several conditions where the use of Femistad is typically not recommended or contraindicated due to an increased risk of serious complications. These include:

Condition
A history of or active blood clots, such as deep vein thrombosis (DVT), pulmonary embolism (PE), or blood clots in the eye (retinal vein/artery occlusion).
Cerebral vascular or coronary artery disease, or a history of a stroke or heart attack.
Known thrombophilic conditions (inherited or acquired blood disorders that increase clotting risk).
Severe kidney disease or severe impairment of renal function.
Certain types of unexplained vaginal bleeding.
Known allergy or hypersensitivity to tranexamic acid.
Active convulsive disorders or a history of convulsions (epilepsy).

It is essential to inform a healthcare provider about any existing medical conditions or medications, especially hormonal contraceptives, as these may also increase the risk of blood clots. Femistad is not intended for use in women who are postmenopausal or those who are pregnant.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Femistad (desogestrel/ethinylestradiol) may interact with a range of medicinal products by altering the concentration of the contraceptive hormones in the body. These pharmacokinetic interactions can potentially decrease the product’s effectiveness or alter the effects of co-administered drugs.

Interacting Product Category Official Regulatory Constraint Mechanistic Basis
Enzyme Inducers Use an alternative, non-hormonal method during co-administration and for 28 days after stopping the interacting product. These substances (e.g., rifampicin, phenytoin, carbamazepine, St. John’s wort) induce hepatic enzymes, primarily CYP3A4, which increases the clearance and reduces the plasma concentration of the contraceptive hormones.
Hepatitis C Combinations Co-administration is contraindicated with drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the risk of liver enzyme elevation. Not to be combined due to high risk of adverse liver-related effects.
Other Drugs May affect the plasma concentrations of certain co-administered drugs. The product itself can inhibit the metabolism of drugs like ciclosporin, leading to potentially increased plasma levels of those drugs.

Additional interactions exist with substances that may interfere with gastrointestinal absorption (e.g., severe vomiting/diarrhoea), requiring procedural management as per official guidance. The primary clinical implication across the regulatory profile is the necessity for backup or alternative contraception when combining the product with enzyme-inducing medicinal products or herbal remedies.

Advertisements

Mechanism of Action

Targeted Receptor Modulation

Femistad's action begins as a selective modulator on specific receptors within defined biological pathways. By binding to these targets, the drug initiates an alteration of initial signaling events, acting to either activate or block the cellular response.


Cascade Modulation and Signal Transduction

This interaction modifies intracellular signal transduction, impacting the molecular cascade downstream. The mechanism involves modulating signaling sequences that propagate heightened physiological responses throughout the system, influencing the kinetics of cellular communication.


Influence on Pathway Dynamics

The overall mechanistic effect involves influencing the dynamics of dysregulated processes driven by distinct signaling patterns. This activity alters signaling dynamics within the targeted pathways, thereby influencing the systemic effects associated with the drug's mechanistic profile.

Advertisements

Dosage and Administration Information

The administration of Femistad is strictly an oral process, involving the daily ingestion of a pre-dosed tablet. The standard regimen adheres to a 28-day cycle consisting of 21 consecutive days of active hormone tablets, followed by 7 days of inert (placebo) tablets or a defined hormone-free interval. The protocol requires one tablet daily, which must be taken at approximately the same time each day to maintain a consistent systemic hormonal presence.

Official Dosing and Administration Principles

Instruction Regulatory Principle
Route of Administration Oral administration only.
Daily Timing One tablet must be taken once every 24 hours at the same time each day.
Regimen Starting Use is initiated via either the Day 1 start (first day of menstruation) or the Sunday start protocol.
Administration Context The tablet may be taken with or without food and a small amount of liquid.
Population Use The dosing regimen established for adults is also used for postpubertal adolescents.
Cycle Constraints The active dose strength is 0.15 mg Desogestrel and 0.03 mg Ethinyl Estradiol per tablet for the 21 active days.

This cyclic protocol is designed for continuous, long-term use for as long as the indicated need persists. The labeling mandates the use of a non-hormonal barrier method for the first 7 consecutive days if the tablet regimen is not started on the first day of the menstrual cycle. Furthermore, the protocol includes a specific procedure to follow if an active tablet is missed, highlighting the importance of uninterrupted daily dosing.

Advertisements

Recent Clinical Evidence

Femistad: Recent Clinical Evidence

Femistad is a combination hormonal preparation containing dienogest (a progestin) and ethinylestradiol (an estrogen). Clinical research has focused on the effect of this combination in contraception, as well as on managing symptoms associated with hormonal conditions.


Studies on Dysmenorrhea and Endometriosis

Clinical trials have investigated the use of this combination therapy for primary dysmenorrhea (common menstrual pain) and endometriosis-associated pelvic pain.

  • Dysmenorrhea: Multiple studies have shown that combined hormonal contraceptives (CHCs) containing dienogest and ethinylestradiol are associated with a substantial reduction in the number of days women experience dysmenorrheic pain. One Phase IIIb trial reported that both the dienogest/ethinylestradiol combination and a standard ethinylestradiol/levonorgestrel combination led to a comparable, considerable relief in self-assessed dysmenorrheic complaints.
  • Endometriosis-Associated Pain: Continuous administration of a combined oral contraceptive containing dienogest and ethinylestradiol has been explored in women with endometriosis-associated pelvic pain. Research reports suggest that this continuous regimen may be associated with an improvement in quality of life (QoL) and a reduction in pelvic pain, with some comparisons suggesting better outcomes than traditional cyclic regimens.

Safety and Long-Term Data

Long-term observational studies of dienogest alone (which is a component of Femistad) used in the management of endometriosis have followed patients for up to five years. These studies track outcomes related to efficacy, patient tolerability, and the profile of reported adverse events over time. This research helps inform the overall understanding of the drug’s long-term administration profile.

Key Studies & References

  1. Evidence-based guideline for the management of primary dysmenorrhea
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Femistad (FAQ)

Q: How quickly does Femistad usually start working?

A: For its intended contraceptive purpose, official information indicates that the active hormones achieve maximum levels in the blood within a few hours of administration. However, full efficacy relies on consistent daily administration, as noted in the product labeling. Official guidance typically notes the use of non-hormonal barrier methods for the first seven days if the start of treatment is not aligned with the menstrual cycle.


Q: Can Femistad cause weight gain, according to regulatory information?

A: Yes, according to the official product information for the hormonal formulation of Femistad, weight increase is listed as one of the common adverse reactions reported in clinical studies.


Q: Is it common to feel tired when starting Femistad?

A: Official information for the formulation containing tranexamic acid (used for heavy menstrual bleeding) indicates that unusual tiredness or weakness may occur as a common side effect.


Q: Can I take Femistad if I also take a common over-the-counter pain reliever?

A: This depends on the specific formulation and pain reliever. The hormonal version of Femistad may increase the risk of serious blood clots when combined with certain common pain relievers (NSAIDs). The tranexamic acid formulation generally shows no known interaction with acetaminophen, but combined hormonal contraceptives are contraindicated due to the risk of thrombosis. It is recommended that individuals review all current medications with a healthcare provider.


Q: Is the active ingredient in Femistad found in any natural substances?

A: Official information notes that Femistad's active ingredients are synthetic preparations. The progestin component, such as Desogestrel, is derived semi-synthetically from naturally occurring plant steroids, but the final active components are synthetic, as noted in the official monographs.


Q: Are there any specific foods or drinks to avoid while taking Femistad?

A: Official product information for the hormonal combination advises caution regarding the consumption of grapefruit or grapefruit juice. Regulatory sources indicate that grapefruit may potentially increase the concentration of the hormonal components in the body.


Q: Is Femistad known to affect mood or cause anxiety?

A: Studies and official information for the hormonal formulation indicate that depressed mood, mood altered, and nervousness have been listed as adverse reactions. These effects are reported across a range of frequencies in patients using the Desogestrel/Ethinyl Estradiol combination.


Q: What does the term 'contraindication' mean in relation to Femistad?

A: A contraindication is a specific condition or circumstance where official documents strongly advise against using a medicine because it carries an increased risk of harm. For Femistad, examples include a history of certain blood clots or severe liver disease.


Q: Does alcohol consumption affect the safety of Femistad?

A: Official hormonal product information does not specify a major direct interaction with alcohol. However, chronic alcohol use is sometimes associated with liver issues, and pre-existing severe liver disease is listed as a contraindication for the hormonal formulation.


Q: Is Femistad a branded medication or is a generic version available?

A: Femistad is often a brand name for a combination drug. Regulatory records, such as those from the FDA, indicate that generic versions of the Desogestrel and Ethinyl Estradiol combination drug are available.


Q: Why does Femistad have a black box warning, if applicable?

A: The hormonal combination medication carries an official Boxed Warning. This warning highlights the increased risk of serious cardiovascular events, such as stroke and heart attack, particularly in women over 35 who smoke.


Q: How does Femistad relate to hormone replacement therapy?

A: While Femistad contains hormones (estrogen and progestin), its approved use is for contraception (preventing pregnancy) or menorrhagia (heavy bleeding), not for Hormone Replacement Therapy (HRT) for postmenopausal symptoms. Official documents state the product is not indicated for use in postmenopausal women.


Q: Can Femistad affect the results of common lab tests?

A: Yes, official product labeling indicates that the use of hormonal contraceptives can influence the results of certain laboratory tests. These include tests that measure blood clotting factors and specific proteins in the blood, such as Sex Hormone-Binding Globulin (SHBG).


Q: Are there different strengths or formulations of Femistad available?

A: Yes, regulatory documents confirm that the product is available in various dosage strengths or formulations of the active ingredients, which contain different amounts of Desogestrel and Ethinyl Estradiol.


Q: What if I take Femistad with caffeine?

A: Studies indicate that the estrogen component, Ethinyl Estradiol, may increase the concentration of caffeine in the bloodstream. This may be associated with an increased potential for caffeine-related side effects.


Q: Is Femistad a controlled substance?

A: According to regulatory authorities, the active ingredients in both the hormonal and tranexamic acid formulations of Femistad are not currently classified as controlled substances.


Q: What is the definition of a 'serious' side effect for Femistad?

A: Official regulatory guidance generally defines a serious side effect as one that results in death, is life-threatening, requires hospitalization, causes disability, or results in a congenital anomaly (birth defect).


Q: What is the difference between a side effect and a drug interaction?

A: A side effect is an unwanted effect that is attributed to the drug itself. A drug interaction occurs when another substance, such as another medicine or a specific food, changes the effect of Femistad or vice-versa.

Advertisements

How should Femistad be stored and disposed of?

How to Store and Dispose of Femistad?

Official guidelines for storing Femistad (Desogestrel and Ethinyl Estradiol) focus on maintaining product stability and ensuring safety. The tablets must be stored at Controlled Room Temperature, defined as 15 C to 30 C (59 F to 86 F), and must be protected from excess heat and moisture.

Storage Requirements

The medication should remain in its original container and be kept tightly closed. A critical safety requirement is that Femistad must be stored out of the sight and reach of children.

Disposal Requirements

Do not flush unused or expired tablets down the toilet or throw them directly into household trash. The preferred method is using an official drug take-back program. If this is not an option, the tablets must be mixed with an undesirable substance, placed in a sealed container, and then discarded in the trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Femistad found in:

A-Z Index: